Corporate Profile

Enalare Therapeutics Inc. is a privately owned clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from acute respiratory conditions.

Press Releases

January 30th, 2025

Enalare Therapeutics Receives Second Component of National Institute of Health (NIH) Grant award to Fund the Next Human Study for ENA-001

Funding from the NIH’s National Institute on Drug Abuse (NIDA) will Support Development of ENA-001, an Agnostic Respiratory Stimulant, for Community Drug Overdose and as a Medical Countermeasure

November 14th, 2024

Enalare Therapeutics is Granted a New Patent for ENA-001, Extending Its Exclusivity in the U.S. to 2043

The New Patent Covers ENA-001 Methods of Treating Respiratory Depression Caused by Propofol, a Widely Used, Centrally Acting Anesthetic.

September 24th, 2024

Enalare Therapeutics Receives FDA Clearance to Initate First Phase 1 Clinical Study of ENA-001 to be Conducted in the United States

The study will consist of utilizing both Enalare’s new Intramuscular formulation (IM), developed with funding provided by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, as well as an intravenous formulation (IV) via a bolus injection.

See More Press Releases

Publications

Reversal of Propofol-induced Depression of the Hypoxic Ventilatory Response by BK-channel Blocker ENA-001: A Randomized Controlled Trial

Simone C Jansen, Maarten van Lemmen, Erik Olofsen, Laurence Moss, Joseph V Pergolizzi Jr, Thomas Miller, Robert D Colucci, Monique van Velzen, Philip Kremer, Albert Dahan, Rutger van der Schrier, Marieke Niesters

Opioid Overdose: Limitations in Naloxone Reversal of Respiratory Depression and Prevention of Cardiac Arrest

Maarten van Lemmen, B.Sc., Jeffrey Florian, Ph.D., Zhihua Li, Ph.D., Monique van Velzen, Ph.D., Eveline van Dorp, M.D., Ph.D., Marieke Niesters, M.D., Ph.D., Elise Sarton, M.D., Ph.D., Erik Olofsen, Ph.D., Rutger van der Schrier, M.D., David G. Strauss, M.D., Ph.D., Albert Dahan, M.D., Ph.D.

A Novel Agnostic Respiratory Stimulant as a Treatment for Apnea of Prematurity: A Proof-of-Concept Study

Thomas L. Miller, Ph.D., Lynn M. Raab, MD, Thomas H. Shaffer, MS.E., Ph.D, Alfred Schweikert, Ph.D., RAC, Frank Diana, Ph.D., Prem Fort, MD, Alana S. Frum, LVTg, RVTg, BASVT, Joseph Pergolizzi, Jr., MD, Robert B. Raffa, Ph.D.

See More Publications